Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript February 24, 2026

Fulcrum Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.32095 EPS, expectations were $-0.31.

Operator: Good morning, and welcome to the Fulcrum Therapeutics conference call to discuss 12-week data from the 20-milligram cohort of the Phase 1b PIONEER trial of pociridir in sickle cell disease. [Operator Instructions] This call is being webcast live and can be accessed on the...